Moore G L, Ledford M E, Unruh K A, Brummell M R
Transfusion. 1981 Nov-Dec;21(6):699-701. doi: 10.1046/j.1537-2995.1981.21682085758.x.
The modified CPD-adenine anticoagulants CPDA-2 and CPDA-3 were developed to improve red blood cell storage to 35 days, since CPDA-1 was found marginal at 35 days in high hematocrit samples. In this study red blood cell storage was extended to 56 days. In vitro correlates of viability were monitored to determine the feasibility of evaluating in vivo the ability of CPDA-2 and CPDA-3 to extend storage past 35 days. The data suggest that red blood cells stored up to 56 days may have acceptable viability, providing the possibility of extended storage for the military and certain special civilian situations.
改良的CPD-腺嘌呤抗凝剂CPDA-2和CPDA-3是为将红细胞储存期延长至35天而研发的,因为发现CPDA-1在高血细胞比容样本中35天时效果不佳。在本研究中,红细胞储存期延长至56天。监测了活力的体外相关指标,以确定评估CPDA-2和CPDA-3在体内将储存期延长至超过35天的能力的可行性。数据表明,储存长达56天的红细胞可能具有可接受的活力,这为军队和某些特殊民用情况提供了延长储存的可能性。